• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Venetoclax and Bortezomib in Relapsed/Refractory Early T-Cell Precursor Acute Lymphoblastic Leukemia.

作者信息

La Starza Roberta, Cambò Benedetta, Pierini Antonio, Bornhauser Beat, Montanaro Anna, Bourquin Jean-Pierre, Mecucci Cristina, Roti Giovanni

机构信息

Universitá degli Studi di Perugia, Perugia, Italy.

出版信息

JCO Precis Oncol. 2019 Sep 20;3. doi: 10.1200/PO.19.00172. eCollection 2019.

DOI:10.1200/PO.19.00172
PMID:32923866
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7448796/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e23d/7448796/9e4973fdc3ce/PO.19.00172f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e23d/7448796/9e4973fdc3ce/PO.19.00172f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e23d/7448796/9e4973fdc3ce/PO.19.00172f1.jpg

相似文献

1
Venetoclax and Bortezomib in Relapsed/Refractory Early T-Cell Precursor Acute Lymphoblastic Leukemia.维奈托克和硼替佐米用于复发/难治性早期T细胞前体急性淋巴细胞白血病
JCO Precis Oncol. 2019 Sep 20;3. doi: 10.1200/PO.19.00172. eCollection 2019.
2
The combination of bortezomib with chemotherapy to treat relapsed/refractory acute lymphoblastic leukaemia of childhood.硼替佐米联合化疗治疗儿童复发/难治性急性淋巴细胞白血病。
Br J Haematol. 2017 Feb;176(4):629-636. doi: 10.1111/bjh.14505. Epub 2017 Jan 24.
3
Treatment of children with relapsed and refractory acute lymphoblastic leukemia with mitoxantrone, vincristine, pegaspargase, dexamethasone, and bortezomib.米托蒽醌、长春新碱、培门冬酶、地塞米松和硼替佐米治疗复发/难治性儿童急性淋巴细胞白血病。
Pediatr Blood Cancer. 2020 Mar;67(3):e28062. doi: 10.1002/pbc.28062. Epub 2019 Nov 14.
4
Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma.维奈托克和纳武利尤单抗联合化疗治疗复发或难治性急性淋巴细胞白血病和淋巴母细胞淋巴瘤患者。
Cancer Discov. 2021 Jun;11(6):1440-1453. doi: 10.1158/2159-8290.CD-20-1465. Epub 2021 Feb 16.
5
Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia. Venetoclax 联合化疗治疗复发或难治性 T 细胞急性淋巴细胞白血病的临床经验。
Clin Lymphoma Myeloma Leuk. 2020 Apr;20(4):212-218. doi: 10.1016/j.clml.2019.09.608. Epub 2019 Sep 30.
6
Targeted therapy using larotrectinib and venetoclax for the relapsed/refractory T-cell acute lymphoblastic leukemia harboring a cryptic ETV6-NTRK3 fusion.针对隐匿性 ETV6-NTRK3 融合的复发/难治性 T 细胞急性淋巴细胞白血病，采用拉罗替尼和维奈托克进行靶向治疗。
Mol Carcinog. 2023 Jul;62(7):899-906. doi: 10.1002/mc.23534. Epub 2023 Apr 10.
7
The role of daratumumab in relapsed/refractory CD38 positive acute leukemias-case report on three cases with a literature review.达雷妥尤单抗在复发/难治性CD38阳性急性白血病中的作用——三例病例报告及文献综述
Front Oncol. 2023 Oct 24;13:1228481. doi: 10.3389/fonc.2023.1228481. eCollection 2023.
8
Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB.硼替佐米与CK2抑制剂CX-4945对急性淋巴细胞白血病的协同细胞毒性作用：关闭促生存内质网伴侣蛋白BIP/Grp78并激活促凋亡核因子κB
Oncotarget. 2016 Jan 12;7(2):1323-40. doi: 10.18632/oncotarget.6361.
9
A successful case of venetoclax-based therapy in relapsed/refractory secondary plasma cell leukemia.维奈托克治疗复发/难治性继发性浆细胞白血病的成功案例。
J Oncol Pharm Pract. 2020 Jul;26(5):1274-1278. doi: 10.1177/1078155219895072. Epub 2019 Dec 22.
10
Venetoclax-based salvage therapy for adult patients with relapsed/refractory acute lymphoblastic leukemia.基于 Venetoclax 的挽救疗法治疗成人复发/难治性急性淋巴细胞白血病。
Eur J Haematol. 2023 Sep;111(3):365-372. doi: 10.1111/ejh.14015. Epub 2023 May 31.

引用本文的文献

1
Combination of venetoclax with CHG regimen in refractory/relapsed T-lymphoblastic lymphoma/acute lymphoblastic leukemia: a case series and literature review.维奈托克与CHG方案联合治疗难治性/复发性T淋巴细胞淋巴瘤/急性淋巴细胞白血病：病例系列及文献综述
Discov Oncol. 2025 Jul 1;16(1):1202. doi: 10.1007/s12672-025-03055-4.
2
Venetoclax combination with Cladribine, idarubicin, Cytarabine for relapsed T-Cell acute lymphoblastic leukemia/lymphoblastic lymphoma treatment: A case report and literature review.维奈托克联合克拉屈滨、伊达比星、阿糖胞苷治疗复发的T细胞急性淋巴细胞白血病/淋巴细胞淋巴瘤：一例报告及文献综述
Leuk Res Rep. 2025 Mar 14;23:100506. doi: 10.1016/j.lrr.2025.100506. eCollection 2025.
3

本文引用的文献

1
Strategies to Overcome Resistance Mechanisms in T-Cell Acute Lymphoblastic Leukemia.克服 T 细胞急性淋巴细胞白血病耐药机制的策略。
Int J Mol Sci. 2019 Jun 20;20(12):3021. doi: 10.3390/ijms20123021.
2
First report of clinical response to Venetoclax in Early T-cell Precursor Acute Lymphoblastic Leukemia.维奈托克治疗早期T细胞前体急性淋巴细胞白血病临床反应的首例报告
JCO Precis Oncol. 2018;2. doi: 10.1200/PO.18.00127. Epub 2018 Aug 22.
3
New Approaches to the Management of Adult Acute Lymphoblastic Leukemia.成人急性淋巴细胞白血病的新型管理方法
Venetoclax-based low-intensity chemotherapy in the salvage treatment of relapsed/refractory T-cell acute lymphoblastic leukemia.
基于维奈托克的低强度化疗用于复发/难治性T细胞急性淋巴细胞白血病的挽救治疗
Clin Exp Med. 2025 Apr 2;25(1):104. doi: 10.1007/s10238-025-01638-7.
4
A metabolic synthetic lethality of phosphoinositide 3-kinase-driven cancer.磷脂酰肌醇3-激酶驱动的癌症的代谢合成致死性。
Nat Commun. 2025 Mar 4;16(1):2191. doi: 10.1038/s41467-025-57225-7.
5
Bortezomib and low dose venetoclax therapy for relapsed/refractory B-cell acute lymphoblastic leukemia with IDH1 mutation.硼替佐米与低剂量维奈克拉联合治疗伴有异柠檬酸脱氢酶1（IDH1）突变的复发/难治性B细胞急性淋巴细胞白血病
Hematol Transfus Cell Ther. 2024 Dec;46 Suppl 6(Suppl 6):S435-S437. doi: 10.1016/j.htct.2024.04.131. Epub 2024 Sep 20.
6
Acute lymphoblastic leukaemia.急性淋巴细胞白血病。
Nat Rev Dis Primers. 2024 Jun 13;10(1):41. doi: 10.1038/s41572-024-00525-x.
7
IDH2-mutated near ETP-ALL with aggressive leukemia cutis and brisk response to venetoclax and decitabine.伴有侵袭性白血病性皮肤病变且对维奈克拉和地西他滨反应迅速的IDH2突变型近ETP-ALL
Leuk Res Rep. 2023 Dec 30;21:100408. doi: 10.1016/j.lrr.2023.100408. eCollection 2024.
8
[Clinical efficacy and safety of venetoclax combined with multidrug chemotherapy in the treatment of 15 patients with relapsed or refractory early T-cell precursor acute lymphoblastic leukemia].维奈托克联合多药化疗治疗15例复发或难治性早期T细胞前体急性淋巴细胞白血病的临床疗效与安全性
Zhonghua Xue Ye Xue Za Zhi. 2023 Aug 14;44(8):649-653. doi: 10.3760/cma.j.issn.0253-2727.2023.08.006.
9
Nelarabine: when and how to use in the treatment of T-cell acute lymphoblastic leukemia.奈拉滨：在 T 细胞急性淋巴细胞白血病治疗中的应用时机和方法。
Blood Adv. 2024 Jan 9;8(1):23-36. doi: 10.1182/bloodadvances.2023010303.
10
Outcomes of adult patients with early T-cell precursor (ETP) acute lymphoblastic leukemia/lymphoma (ALL) and non-ETP T-ALL.成人早期 T 细胞前体（ETP）急性淋巴细胞白血病/淋巴瘤（ALL）和非 ETP T-ALL 患者的结局。
Int J Hematol. 2023 May;117(5):738-747. doi: 10.1007/s12185-023-03546-6. Epub 2023 Feb 9.
J Clin Oncol. 2018 Sep 21:JCO2017773648. doi: 10.1200/JCO.2017.77.3648.
4
Venetoclax in Combination with Decitabine for Relapsed T-Cell Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplant.维奈托克联合地西他滨用于异基因造血细胞移植后复发的T细胞急性淋巴细胞白血病
Case Rep Hematol. 2018 Aug 26;2018:6092646. doi: 10.1155/2018/6092646. eCollection 2018.
5
The MCL1-specific inhibitor S63845 acts synergistically with venetoclax/ABT-199 to induce apoptosis in T-cell acute lymphoblastic leukemia cells.MCL1特异性抑制剂S63845与维奈托克/ABT-199协同作用，诱导T细胞急性淋巴细胞白血病细胞凋亡。
Leukemia. 2019 Jan;33(1):262-266. doi: 10.1038/s41375-018-0201-2. Epub 2018 Jul 15.
6
The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia.儿童及青年T细胞系急性淋巴细胞白血病的基因组图谱
Nat Genet. 2017 Aug;49(8):1211-1218. doi: 10.1038/ng.3909. Epub 2017 Jul 3.
7
Potential mechanisms of resistance to venetoclax and strategies to circumvent it.对维奈克拉耐药的潜在机制及克服耐药的策略。
BMC Cancer. 2017 Jun 2;17(1):399. doi: 10.1186/s12885-017-3383-5.
8
Pathways and mechanisms of venetoclax resistance.维奈克拉耐药的途径和机制。
Leuk Lymphoma. 2017 Sep;58(9):1-17. doi: 10.1080/10428194.2017.1283032. Epub 2017 Jan 31.
9
Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia.体外药物反应分析检测耐药急性淋巴细胞白血病中的复发性敏感性模式。
Blood. 2017 Mar 16;129(11):e26-e37. doi: 10.1182/blood-2016-09-738070. Epub 2017 Jan 25.
10
Multi-center analysis of the effect of T-cell acute lymphoblastic leukemia subtype and minimal residual disease on allogeneic stem cell transplantation outcomes.T细胞急性淋巴细胞白血病亚型及微小残留病对异基因干细胞移植结局影响的多中心分析
Bone Marrow Transplant. 2017 Jan;52(1):20-27. doi: 10.1038/bmt.2016.194. Epub 2016 Sep 12.